Research progress of peripheral blood biomarkers related to immune checkpoint inhibitors
Precision treatment of cancer has entered the era of immunotherapy represented by immune checkpoint inhibitors(ICIs).Tumor tissue-based detection,such as programmed cell death-ligand 1 and tumor mutational burden are common biomarkers used in clinical screening for the benefit groups of ICIs.However,the wide application of tissue-based detection has been limited for insufficient tumor tissue samples and the need for invasive and complex operation.The recent rise of peripheral blood biomarkers pro-vides an alternative non-invasive solution to address these defects.This review summarizes the research progress of peripheral blood biomarkers related to immune checkpoint inhibitors,in order to provide references in clinic for screening groups benefiting from ICIs.
国家科技期刊平台
NSTL
万方数据
